CD274 and neoplasm: Nivolumab monotherapy demonstrated survival benefits for patients with heavily pretreated GC/GEJC, regardless of tumor PD-L1 expression: the median OS was 5.22 months in the nivolumab group and 3.83 months in the placebo group (HR, 0.51; 95% CI, 0.21–1.25) in patients with PD-L1 ≥ 1% GC/GEJC (n = 26) and 6.05 and 4.19 months (HR, 0.72; 95% CI, 0.49–1.05), respectively, in patients with PD-L1 < 1% GC/GEJC (n = 166).